1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,161 | 0,208 | 08:03 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.07. | Diagnostear Technologies Inc: Diagnostear analyzes TeaRx, enzyme immunoassay | 1 | Stockwatch | ||
| 09.07. | DiagnosTear Technologies Inc.: DiagnosTear Announces Interim Clinical Study Results Demonstrating Excellent Correlation Between TeaRx Red Eye and Quantitative ELISA Testing | 477 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - July 9, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics... ► Artikel lesen | |
| 05.06. | Diagnostear Technologies Inc: Diagnostear publishes TeaRx dry-eye study results | 3 | Stockwatch | ||
| 05.06. | DiagnosTear Technologies Inc.: DiagnosTear Achieves Major Scientific Milestone with Publication of TeaRx Clinical Study in Current Eye Research Journal | 488 | Newsfile | Publication in a leading peer-reviewed ophthalmology journal further validates TeaRx as a novel point-of-care platform for diagnosis, patient stratification, and prediction of responsiveness to... ► Artikel lesen | |
| 15.05. | Bahnbrechende KI: Ohne Nadeln zum Blutbild! | bullVestor | |||
| 12.05. | DiagnosTear Technologies Inc.: DiagnosTear Secures Exclusive Global Rights to CLARIFY Eye Imaging Platform for Needle-Free Blood Diagnostics | 686 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - May 12, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a leader in rapid, eye-based diagnostic technologies... ► Artikel lesen | |
| DIAGNOSTEAR TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 08.05. | Diagnostear Technologies Inc: Diagnostear shareholders approve all matters at AGM | 1 | Stockwatch | ||
| 07.05. | DiagnosTear Technologies Inc.: DiagnosTear Technologies Inc. Announces Results of AGM | 404 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce results of its annual general... ► Artikel lesen | |
| 05.05. | Diagnostear Technologies Inc: Diagnostear Technologies extends warrants | 17 | Stockwatch | ||
| 21.04. | DiagnosTear Technologies Inc.: DiagnosTear Technologies Inc. Announces Adoption of Semi-Annual Reporting | 646 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - April 21, 2026) - DiagnosTear Technologies Inc. ("DiagnosTear" or the "Company") announces that it has adopted a semi-annual financial reporting ("SAR")... ► Artikel lesen | |
| 26.02. | DiagnosTear Technologies Inc.: DiagnosTear Announces Regulatory Approvals in France and Study Initiation with AlyaTec for TeaRx Red Eye | 542 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care... ► Artikel lesen | |
| 21.02. | Diagnostear Technologies Inc: Diagnostear signs U.K. LOI with Hanson Medical | 9 | Stockwatch | ||
| 20.02. | DiagnosTear Technologies Inc.: DiagnosTear Advances UK Market Entry Through Commercial Collaboration with Hanson Medical | 1.005 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 20, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a developer of rapid point-of-care diagnostics... ► Artikel lesen | |
| 22.01. | DiagnosTear Technologies Inc.: DiagnosTear Signs Letter of Intent to Advance Commercial Expansion of TeaRx in India | 486 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 22, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics... ► Artikel lesen | |
| 17.01. | DiagnosTear Technologies Inc.: DiagnosTear Announces Interim Clinical Results Indicating High Efficiency from TeaRx Red Eye | 894 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care... ► Artikel lesen | |
| 18.12.25 | DiagnosTear Technologies Inc.: DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count | 875 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a leader in rapid eye based diagnostic technologies... ► Artikel lesen | |
| 09.12.25 | DiagnosTear Technologies Inc. - Confirmation of No Material Change | 613 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - December 9, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular... ► Artikel lesen | |
| 02.12.25 | DiagnosTear Technologies Inc.: DiagnosTear Announces Clinical Study with AlyaTec to Advance Analytical Validation and FDA Submission Pathway of TeaRx Red Eye Diagnostic Test | 594 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - December 2, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular... ► Artikel lesen | |
| 26.11.25 | DiagnosTear Technologies Inc.: DiagnosTear Technologies Announces Initiation of a Collaboration with LV Prasad Eye Institute for Advancing the Clinical Validation of TeaRx Red Eye Diagnostic Test | 570 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - November 26, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) ("DiagnosTear" or the "Company"), a leader in developing cutting-edge point-of-care eye... ► Artikel lesen | |
| 18.11.25 | DiagnosTear Technologies Inc. Announces Closing of Private Placement of Units | 531 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") Further to its press release from June 3, 2025... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 44,990 | +1,06 % | Aktien Frankfurt: 'Old economy' schiebt Dax weiter in Richtung Rekordhoch | FRANKFURT (dpa-AFX) - Die weiter nachgebenden Energiepreise haben am deutschen Aktienmarkt am Dienstag für weitere Entspannung gesorgt. Der Dax knüpfte gegen Mittag mit plus 0,61 Prozent auf 25.517... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 38,510 | +4,48 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 31,840 | +4,39 % | BERENBERG stuft CARL ZEISS MEDITEC AG auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Carl Zeiss Meditec von 30 auf 28 Euro gesenkt und die Einstufung auf "Hold" belassen. Das Geschäftsjahr 2025/26 sei für Carl... ► Artikel lesen | |
| INTUITIVE SURGICAL | 310,80 | +1,42 % | Intuitive Surgical: Was UBS nach dem Rücksetzer sieht | ||
| DRAEGERWERK | 112,80 | +3,11 % | EQS-News: Drägerwerk AG & Co. KGaA: Dräger mit starker Geschäftsentwicklung im ersten Halbjahr 2026 | EQS-News: Drägerwerk AG & Co. KGaA
/ Schlagwort(e): Halbjahresbericht/Kapitalmarkttag
Drägerwerk AG & Co. KGaA: Dräger mit starker Geschäftsentwicklung im ersten Halbjahr 2026... ► Artikel lesen | |
| MEDTRONIC | 74,94 | +1,16 % | Intuitive Surgical (ISRG) vs. Medtronic (MDT): Which MedTech Stock Looks Better Positioned for Growth? | ||
| THERMO FISHER | 492,00 | -1,20 % | Analysts Appear Bullish on Thermo Fisher (TMO): Is The Stock Really a Buy After Earnings? | ||
| TELADOC HEALTH | 5,862 | +0,83 % | Teladoc Health: Insurance Demand Outpaces Provider Capacity As BetterHelp Revenue Falls 12% | ||
| HIMS & HERS HEALTH | 24,140 | +0,25 % | Hims & Hers-Aktie: Folgt der nächste Wachstumsturbo? | Die Aktie von Hims & Hers Health hat sich in den vergangenen Jahren zu einem der spektakulärsten Wachstumswerte im Gesundheitssektor entwickelt. Die operativen Kennzahlen sprechen weiterhin für erhebliches... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 59,71 | 0,00 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 14,855 | +0,03 % | Alignment Healthcare Reports Second Quarter 2026 Results, Surpassing High End of Guidance Across All Key Metrics | Generates $1.3 billion in total revenue, representing 31.6% growth year-over-year Grows Medicare Advantage membership 31.5% year-over-year to approximately 294,100 membersRaises the midpoint of all... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 23,670 | 0,00 % | Privia Health Group, Inc.: Privia Health Reports First Quarter 2026 Financial Results | Strong First Quarter Performance and Operating ExecutionReiterated Full-Year 2026 Guidance Reflects Continued Momentum ARLINGTON, Va., May 07, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq:... ► Artikel lesen | |
| BILLIONTOONE | 138,54 | -0,04 % | BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar | Renowned physician-scientist, former Director of Frederick National Laboratory, and one of the nation's most accomplished leaders in oncology joins BillionToOne... ► Artikel lesen | |
| GENEDX | 65,07 | -0,06 % | NSE - GeneDx Holdings Corp. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| HEARTFLOW | 25,230 | 0,00 % | Baird startet Coverage für HeartFlow mit "Outperform" |
DIAGNOSTEAR TECHNOLOGIES INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,161 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAGNOSTEAR TECHNOLOGIES INC finden Sie auf Wallstreet Online.